Live Feeds
● LIVE Updated 3h ago · 8 sources tracked

Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century

Biotech startup Enveda has raised $311 million in Series E funding to advance AI-discovered, nature-derived medicines. The funding round values the company at $2 billion, doubling its previous valuation. Enveda intends to use the capital to move more candidates into clinical trials, focusing specifically on inflammatory diseases and late-stage obesity treatments. The company aims to develop medicines that address life after GLP-1 drugs and seeks to establish itself as a household name in the pharmaceutical industry.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Enveda raised $311 million in Series E funding.
  • ✓ The company is now valued at $2 billion.
  • ✓ Enveda uses AI to discover drugs from the natural world.
  • ✓ The funding will support the development of medicines for obesity and inflammatory diseases.
🛡️ Source Corroboration: 8 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Enveda completed a $311 million Series E funding round that increased its valuation to $2 billion.

Live updates

  1. Enveda Secures $311 Million Series E Funding at $2 Billion Valuation

    Biotech startup Enveda has raised $311 million in Series E funding to advance AI-discovered, nature-derived medicines. The funding round values the company at $2 billion, doubling its previous valuation. Enveda intends to use the capital to move more candidates into clinical trials, focusing specifically on inflammatory diseases and late-stage obesity treatments. The company aims to develop medicines that address life after GLP-1 drugs and seeks to establish itself as a household name in the pharmaceutical industry.

    Why it matters

    Enveda uses artificial intelligence to analyze the chemistry of the natural world for drug discovery. This approach seeks to modernize pharmaceutical development by integrating AI with nature-derived compounds. The current push into obesity and inflammatory diseases targets high-demand therapeutic areas.

    What is confirmed

    • Enveda raised $311 million in Series E funding.
    • The company is now valued at $2 billion.
    • Enveda uses AI to discover drugs from the natural world.
    • The funding will support the development of medicines for obesity and inflammatory diseases.

    Still unconfirmed

    • Enveda's valuation has doubled to reach the $2 billion mark.
    • The company is developing a drug specifically aimed at life after GLP-1 drugs.
    • Enveda has an ambition to become a household name.

    What to watch next

    • Results from upcoming clinical trials for nature-derived AI drugs
    • Specific naming of the candidates targeting obesity and inflammatory diseases
    Sources used for this update (8)
    1. businesswire.com — Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century
    2. WSJ — Exclusive | AI Biotech Enveda Doubles in Value to $2 Billion
    3. BioSpace — AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
    4. TechCrunch — Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
    5. Fierce Biotech — Enveda reaps $311M series E to feed ambition to become a ‘household name’
    6. digitalmarketreports.com — Enveda Raises $311 Million at $2 Billion Valuation to Advance AI-Discovered Drugs
    7. Longevity.Technology — Nature’s chemistry, read by AI, funded at $311m
    8. theaiinsider.tech — Enveda Raises $311M Series E at $2B Valuation to Advance AI-Discovered Natural Medicines
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community